UK government and CSL Seqirus expand vaccine partnership with first planned AUJEMFLU rollout
The UK government and CSL Seqirus have expanded their vaccine partnership, including plans for the UK to become the first country to introduce AUJEMFLU from the 2027/28 influenza season.
The agreement also extends the companies' pandemic-preparedness Advance Purchase Agreement and supports continued vaccine manufacturing capability at CSL Seqirus' Liverpool site.
The partnership strengthens UK influenza and pandemic-response preparedness while creating a pathway for wider use of an adjuvanted cell-based flu vaccine.
Field | Content |
Alert Type | Deal |
Parties | UK Government; CSL Seqirus |
Deal Type | Strategic vaccine partnership and Advance Purchase Agreement extension |
Asset or Company | AUJEMFLU and UK pandemic influenza vaccine supply |
Therapy Area(s) | Vaccines; infectious disease; public health |
Technology or Modality | Adjuvanted cell-based influenza vaccine |
Planned Rollout | AUJEMFLU from the 2027/28 influenza season |
Manufacturing Site | Liverpool, United Kingdom |
Geography | United Kingdom |
What Happened | The UK government and CSL Seqirus expanded their vaccine partnership, including plans for the UK to become the first country to introduce AUJEMFLU and an extension of their pandemic-preparedness supply agreement. |
Why It Matters | The agreement strengthens domestic vaccine manufacturing and pandemic-response capability while introducing a new influenza vaccine platform into the UK programme. |
Supporting Context | The extended Advance Purchase Agreement supports ongoing readiness for rapid vaccine supply during future influenza pandemics. |
Strategic Rationale | The UK reinforces health-security capacity while CSL Seqirus secures continued strategic support for its Liverpool manufacturing operations. |
Potential Impact | The partnership could improve seasonal influenza protection and preserve rapid-response manufacturing capacity for future pandemics. |
Key Takeaway | The UK and CSL Seqirus are expanding a long-term vaccine partnership combining future AUJEMFLU rollout with strengthened pandemic preparedness. |
What to Watch | Implementation ahead of the 2027/28 flu season, procurement details and future use of the Liverpool site in pandemic planning. |
Primary Source | CSL Seqirus / UK Government |
Relevant Date | 22 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare